Naver D2SF backs ImpriMed in $10m Series A2 bridge round
Naver D2SF, NAVER’s venture arm, invested in Silicon Valley precision medicine firm ImpriMed as it joined ImpriMed’s $10 million Series A2 bridge round.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.